Pharmafile Logo

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring for children with the disease. It also puts a considerable burden on healthcare resources. AD affects up to 20% of children and around 3% of adults worldwide and its prevalence is still increasing, especially in some lower income countries in Asia and Latin America. The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies. Severity varies widely – some people might just suffer from a light rash on a few areas of the body and might get better as they get older, whilst others can suffer from very dry, bleeding and sore skin all over, with regular painful flare-ups, which continue into adulthood. In the US, physicians typically use the Body Surface Index to assess severity of the disease. Around 65% of patients in the US are recognised as suffering from moderate-severe eczema. Severe patients can suffer from more than 15 flare-ups per year, lasting two weeks or more…Read the full article: https://bit.ly/2rkI7jc

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Infographic: Therapy Watch Lupus

Download our latest infographic, which offers an introduction to the real-world patient insights collected by our Therapy Watch Lupus study.

Article: Getting their lives back: Improving options for people with Lupus

Head of Therapy Watch, Helen Parfitt and Head of Living With, Mariel Metcalfe, investigate Lupus from the perspective of both healthcare professionals and patients using data from our syndicated products.

MedTech specialist joins Research Partnership

Janet Powers has joined the company as a Director in the MedTech division.

Interactive: Best Behaviour

Download our curated collection of case studies and other useful resources that illustrate how we apply the principles of behavioural science in our research design.

RP Investigates – Q&A session: Living with Lupus

In this 45-minute session, Head of Living With, Mariel Metcalfe spoke to Brenda, who was diagnosed with Lupus 12 years ago.

Webcast: Demand Assessment

Find out how a study design which better reflects real-world choices can produce a more realistic model for the future market.

White paper: Are we prepared for the influx of CAR-Ts?

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

New syndicated patient report – Living with Lupus US

Living with Lupus US is a new syndicated patient report which offers valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.

Video: Emotion AI

Artificial intelligence is revolutionising the way we conduct healthcare market research.

Report: Mexico’s drug market access landscape shake-up: What does it mean for pharma?

Rebeca Nana Barrantes and Tania Rodrigues outline what the shake-up in Mexico’s drug market access landscape means for pharma.